ARKG241108C29000
- 0.20
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript Summary
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
Here Are the Major Earnings After the Close Today
Where Ionis Pharmaceuticals Stands With Analysts
Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Buy on Veracyte, Raises Price Target to $44
Veracyte Analyst Ratings
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript Summary
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
Recursion Pharmaceuticals EPS of -$0.34 Misses by $0.01, Revenue of $26.1M Misses by $3.73M
Veracyte Non-GAAP EPS of $0.33 Beats by $0.16, Revenue of $115.86M Beats by $6.03M
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript Summary
A Glimpse of Intellia Therapeutics's Earnings Potential
Trending Industry Today: ARK Innovation ETF Leads Gains In ARK ETFs Stocks
Nurix Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Here's the Major Earnings Before the Open Tomorrow
Beam Falls After Fatality in Gene Editing Trial
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary